ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib

Affiliations

• ¹ Department of Oral & Maxillofacial-Head & Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; College of Stomatology, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China; National Clinical Research Center for Oral Diseases, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China.
• ² The Medical Department, 3D Medicines Inc., Shanghai, China.
• ³ College of Stomatology, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China; National Clinical Research Center for Oral Diseases, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China; Department of Oral Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
• ⁴ The First Affiliated Hospital of Soochow University, Soochow, China.
• ⁵ Research and Development Institute of Precision Medicine, 3D Medicines Inc., Shanghai, China.
• ⁶ Department of Oral & Maxillofacial-Head & Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; College of Stomatology, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China; National Clinical Research Center for Oral Diseases, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China. Electronic address: zhang.chenping@hotmail.com.